These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 33251651)

  • 1. Which drugs are best for overactive bladder? From patients' expectations to physicians' decisions.
    Milsom I; Wagg A; Oelke M; Chapple C
    Int J Clin Pract; 2021 Apr; 75(4):e13870. PubMed ID: 33251651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicriteria Decision Analysis Applied to the Clinical Use of Pharmacotherapy for Overactive Bladder Symptom Complex.
    Chapple CR; Mironska E; Wagg A; Milsom I; Diaz DC; Koelbl H; Pushkar D; Tubaro A; De Ridder D; Chartier-Kastler E; Phillips LD
    Eur Urol Focus; 2020 May; 6(3):522-530. PubMed ID: 31623981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
    Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J
    BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fesoterodine clinical efficacy and safety for the treatment of overactive bladder in relation to patient profiles: a systematic review.
    Chapple C; Oelke M; Kaplan SA; Scholfield D; Arumi D; Wagg AS
    Curr Med Res Opin; 2015 Jun; 31(6):1201-43. PubMed ID: 25798911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of the efficacy and safety of fesoterodine for treating overactive bladder and urgency urinary incontinence in elderly patients.
    Wagg A; Oelke M; Angulo JC; Scholfield D; Arumi D
    Drugs Aging; 2015 Feb; 32(2):103-25. PubMed ID: 25673122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
    Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z
    BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.
    Ginsberg D; Schneider T; Kelleher C; Van Kerrebroeck P; Swift S; Creanga D; Martire DL
    BJU Int; 2013 Aug; 112(3):373-85. PubMed ID: 23826844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fesoterodine: a new agent for treating overactive bladder.
    Ellsworth P; Berriman SJ; Brodsky M
    Am J Manag Care; 2009 Mar; 15(4 Suppl):S115-7. PubMed ID: 19355800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials.
    DuBeau CE; Morrow JD; Kraus SR; Creanga D; Bavendam T
    Neurourol Urodyn; 2012 Nov; 31(8):1258-65. PubMed ID: 22907761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Choosing the Most Efficacious and Safe Oral Treatment for Idiopathic Overactive Bladder: A Systematic Review and Network Meta-analysis.
    Mostafaei H; Salehi-Pourmehr H; Jilch S; Carlin GL; Mori K; Quhal F; Pradere B; Grossmann NC; Laukhtina E; Schuettfort VM; Aydh A; Sari Motlagh R; König F; Roehrborn CG; Katayama S; Rajwa P; Hajebrahimi S; Shariat SF
    Eur Urol Focus; 2022 Jul; 8(4):1072-1089. PubMed ID: 34563481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
    Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
    BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No. 353-Treatments for Overactive Bladder: Focus on Pharmacotherapy - An Addendum.
    Geoffrion R
    J Obstet Gynaecol Can; 2017 Dec; 39(12):1221-1229. PubMed ID: 28986184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What are the chances of improvement or cure from overactive bladder? A pooled responder analysis of efficacy and treatment emergent adverse events following treatment with fesoterodine.
    Wagg AS; Herschorn S; Carlsson M; Fernet M; Oelke M
    Neurourol Urodyn; 2021 Aug; 40(6):1559-1568. PubMed ID: 34036630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a predictive model for urgency urinary incontinence.
    Darekar A; Carlsson M; Quinn S; Ntanios F; Mangan E; Arumi D; Scholfield D
    Contemp Clin Trials; 2016 Nov; 51():44-49. PubMed ID: 27687744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial.
    Chapple C; Schneider T; Haab F; Sun F; Whelan L; Scholfield D; Dragon E; Mangan E
    BJU Int; 2014 Sep; 114(3):418-26. PubMed ID: 24552358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service.
    Cardozo L; Thorpe A; Warner J; Sidhu M
    BJU Int; 2010 Aug; 106(4):506-14. PubMed ID: 20132203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolterodine extended release in the treatment of male OAB/storage LUTS: a systematic review.
    Gacci M; Novara G; De Nunzio C; Tubaro A; Schiavina R; Brunocilla E; Sebastianelli A; Salvi M; Oelke M; Gravas S; Carini M; Serni S
    BMC Urol; 2014 Oct; 14():84. PubMed ID: 25348235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A role of fesoterodine in treatment of overactive bladder].
    Kupriyanov YA; Kasyan GR; Pushkar DY
    Urologiia; 2018 Dec; (6):155-162. PubMed ID: 30742396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does fesoterodine have a role in the treatment of poorly managed patients with overactive bladder?
    Morris V; Wagg A
    Drug Des Devel Ther; 2014; 8():113-9. PubMed ID: 24470751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms.
    Serels SR; Toglia MR; Forero-Schwanhaeuser S; He W
    Curr Med Res Opin; 2010 Oct; 26(10):2277-85. PubMed ID: 20707767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.